Baek-Yeol Ryoo et al.272 revealed that DDR gene mutations were found in 62.5% of BTC patients (including 20.2% GBC patients), and that DDR gene mutations associated with longer mPFS (6.9 vs. 5.7 months; P = 0.013) and mOS (21.0 vs. 13.3 months; P = 0.009) in patients with BTC treated with first-line platinum-based chemotherapy for unresectable or metastatic disease. The gene discussed is DDR1; the disease is metastatic neoplasm.